SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02762877

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

A Study to Determine the Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma From Patients With Non Small Cell Lung Carcinoma (NSCLC)

A study to determine the concordance of key actionable genomic alterations as assessed in tumor tissue and plasma from patients with non small cell lung carcinoma (NSCLC)

NCT02762877 Non Small Cell Lung Carcinoma
MeSH:Carcinoma Lung Neoplasms Carcinoma, Non-Small-Cell Lung
HPO:Carcinoma Neoplasm of the lung Non-small cell lung carcinoma


Primary Outcomes

Description: Assess concordance of genomic alterations in EGFR detected in plasma versus tumor tissue in stage IV non squamous NSCLC patients who are newly diagnosed or progressing on treatment.

Measure: EGFR Detected in Plasma Versus Tumor Tissue in Stage IV Non Squamous NSCLC Patients Who Are Newly Diagnosed or Progressing on Treatment

Time: Tumor tissue testing to plasma testing

Secondary Outcomes

Measure: Assess Concordance of Genomic Alterations in ALK (EML4-ALK Fusions) Detected in Plasma Versus Tumor Tissue.

Time: Tumor tissue testing to plasma testing

Measure: Characterize the Detection of EGFR T790M Alterations in Plasma in Patients Progressing on EGFR Targeting Therapy (Erlotinib, Gefitinib, Afatinib).

Time: At time of plasma testing

Time Perspective: Prospective

Other


There is one SNP

SNPs


1 T790M

Characterize the Detection of EGFR T790M Alterations in Plasma in Patients Progressing on EGFR Targeting Therapy (Erlotinib, Gefitinib, Afatinib).. null. --- T790M ---



HPO Nodes


HPO: